Medicina de Emergências
Perspectiva | COVID-19: ascensão e ascensão de Delta.
22 Jun, 2021 | 09:13hCOVID-19: The rise and rise of Delta – Sciblogs
Ivermectina é a nova hidroxicloroquina, parte 2 – “Ivermectina não deve ser usada no tratamento da COVID-19 fora do contexto de um estudo clínico.”
22 Jun, 2021 | 09:11hIvermectin is the new hydroxychloroquine, take 2 – Science-Based Medicine
Relacionado: [Preprint] Meta-analysis of RCT: Ivermectin for the treatment of COVID-19 – no effect on all-cause mortality, length of stay, or viral clearance E M-A: Prophylaxis against Covid-19: 1 – no benefit from Hydroxychloroquine; 2 – as studies on ivermectin so far have been small, it remains very uncertain whether ivermectin reduces SARS-CoV-2 infection E Therapeutics and COVID-19 | WHO guideline update advises Ivermectin should only be used to treat COVID-19 within clinical trials E EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomized clinical trials E FDA: Why you should not use Ivermectin to treat or prevent COVID-19 E RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19 E NIH Guideline Statement: “there are insufficient data to recommend either for or against the use of ivermectin for the treatment of COVID-19” E Video (5min): Ivermectin for COVID-19 | A Doctor Explains
Relato de caso | Síndrome inflamatória multissistêmica em adulto após infecção por SARS-CoV-2.
22 Jun, 2021 | 09:09hM-A | Azitromicina não reduz a necessidade de ventilação mecânica invasiva ou a mortalidade em pacientes com Covid-19.
21 Jun, 2021 | 10:57hRecomendações baseadas em consenso para o tratamento da via aérea complicada, parte 1. Tratamento da via aérea complicada em um paciente inconsciente.
21 Jun, 2021 | 10:49hRecomendações da ECMM/ISHAM para o manejo clínico da mucormicose associada à COVID-19 em países de baixa e média rendas.
18 Jun, 2021 | 10:34hComentário sobre estudo | História da hipotermia na parada cardíaca, 2002-2021 (RIP).
18 Jun, 2021 | 10:29hA history of hypothermia for cardiac arrest, 2002-2021 (RIP) – PulmCrit
Estudo original: RCT: In patients with coma after out-of-hospital cardiac arrest, targeted hypothermia did not improve outcomes.
Comentário no Twitter
A history of hypothermia for cardiac arrest, 2002-2021 (RIP)🪦
🥶2002 studies supporting hypothermia were weak
🥶robust studies refute benefit (TTM1 & TTM2)
🥶growing evidence of iatrogenic harm
🥶post-arrest hypothermia should be restricted to within RCTshttps://t.co/GZbpgHXWoD pic.twitter.com/ILUAiqqLQl— 𝙟𝙤𝙨𝙝 𝙛𝙖𝙧𝙠𝙖𝙨 💊 (@PulmCrit) June 17, 2021
Estudo randomizado | Tofacitinibe reduziu o risco de morte ou insuficiência respiratória em pacientes hospitalizados com pneumonia por Covid-19.
17 Jun, 2021 | 11:06hTofacitinib in Patients Hospitalized with Covid-19 Pneumonia – New England Journal of Medicine
Comunicado de imprensa: Data Published in New England Journal of Medicine Shows Pfizer’s Tofacitinib Meets Primary Endpoint in Brazilian Study in Patients Hospitalized with COVID-19 Pneumonia
Comentário no Twitter:
Patients who were hospitalized with #COVID19 pneumonia were randomly assigned, at a median of 10 days after symptom onset, to receive tofacitinib or placebo. At 28 days, the risk of death or respiratory failure was lower in the tofacitinib group. #IDTwitter
— NEJM (@NEJM) June 16, 2021
[Preprint] Estudo RECOVERY descobre que a combinação de anticorpo monoclonal Regeneron reduz as mortes de pacientes hospitalizados com COVID que não desenvolveram sua própria resposta imunológica.
17 Jun, 2021 | 11:04hComunicado de imprensa: RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response
Estudo original (preprint): Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – medRxiv
Comentários: Monoclonal antibodies cut risk of dying from COVID-19—but only in some patients – Science E Antibody combo cuts COVID deaths by 20% in very ill seronegative patients – CIDRAP E Regeneron antibody saves lives in some hospitalized Covid patients, study finds – STAT E Expert reaction to press release from the RECOVERY trial reporting that Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response – Science Media Centre
Comentário no Twitter
RECOVERY Pre-print:
In patients hospitalised with COVID-19 but no natural antibody response, monoclonal antibody infusion:
– reduced mortality
– increased speed of discharge
– reduced progression to invasive mechanical ventilation or deathhttps://t.co/rpDk4eUhmm pic.twitter.com/wXegKcDZg8— Martin Landray (@MartinLandray) June 16, 2021
Agora, o CDC chama a variante Delta do coronavírus de “variante de preocupação”.
17 Jun, 2021 | 11:02hCDC now calls coronavirus Delta variant a ‘variant of concern’ – CNN
Diretriz: SARS-CoV-2 Variant Classifications and Definitions – Centers for Disease Control and Prevention
Comentário no Twitter
BREAKING—CDC now officially declares #DeltaVariant a “variant of concern”—because much more transmissible (50% faster than #B117, 2x than original strain), more severe (2.5x hospitalization risk than B117, 4x original) & 1 dose vaccine evasive.🧵 #COVID19https://t.co/jZCgfzFLla pic.twitter.com/SszvXuysze
— Eric Feigl-Ding (@DrEricDing) June 15, 2021